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Angiotensin Receptor Blockade Improves
Myocardial Beta-Adrenergic Receptor
Signaling in Postinfarction Left Ventricular Remodeling
A Possible Link Between Beta-Adrenergic
Receptor Kinase-1 and Protein Kinase C Epsilon Isoform
Toshiyuki Takahashi, MD,* Toshihisa Anzai, MD,* Tsutomu Yoshikawa, MD,* Yuichiro Maekawa, MD,*
Keitaro Mahara, MD,* Michikado Iwata, MD,* H. Kirk Hammond, MD,† Satoshi Ogawa, MD*
Tokyo, Japan; and San Diego, California
OBJECTIVES We tested the hypothesis that angiotensin II type 1 receptor blocker (ARB) may improve
beta-adrenergic receptor (AR) coupling in heart failure (HF) after myocardial infarction
(MI).
BACKGROUND Beta-AR desensitization is one of the mechanisms underlying the transition from compen-
sated to decompensated HF. Beta-adrenergic receptor kinase-1 (ARK1), which can be
induced by protein kinase C (PKC) in vitro, is activated in the failing myocardium, resulting
in beta-AR uncoupling.
METHODS Models of MI in rats were produced by ligation of left coronary artery. Four weeks after
surgery, they were randomized to vehicle (MI/control [C]) or candesartan (10 mg/kg/day)
treatment (MI/ARB). Sham-operated rats, or shams, served as controls.
RESULTS After two weeks of treatment, echocardiography and hemodynamics showed that the left
ventricular (LV) dimension increased and that the percent of fractional shortening and
maximum rate of rise in left ventricular pressure (dP/dt) decreased in MI rats compared with
shams. There were no differences in these indexes between MI/C and MI/ARB. An increase
in maximum dP/dt under isoproterenol (ISO) stimulation was attenuated in MI/C but
improved in MI/ARB. Reductions in the percentage of high-affinity sites of beta-AR and
ISO-stimulated cyclic adenosine monophosphate production in noninfarcted myocardium
were also improved by ARB treatment. Up-regulation of beta-ARK1 and PKC-epsilon
isoform protein levels and activation of PKC in noninfarcted myocardium from MI/C were
both inhibited by ARB treatment.
CONCLUSIONS Treatment with ARB during the chronic phase of MI improved beta-AR coupling in
noninfarcted myocardium without affecting basal LV function. Cross-talk between beta-AR
and angiotensin signaling through beta-ARK1 and PKC-epsilon may be responsible for the
phenomenon. (J Am Coll Cardiol 2004;43:125–32) © 2004 by the American College of
Cardiology Foundation
After a large myocardial infarction (MI), progressive left
ventricular (LV) dilation initially occurs as an adaptive
phenomenon to maintain cardiac output. In the chronic
stage, not only is the LV infarct area impaired but also
noninfarcted viable myocardium is affected in response to
subsequent mechanical and numerous hormonal stimuli (1).
This remodeling process results in global contractile dys-
function and the formation of substrates for lethal arrhyth-
mias. Thus, LV remodeling plays a pivotal role in the
pathogenesis of congestive heart failure (HF) after MI.
Although the cellular and molecular mechanisms for the
development of postinfarction LV remodeling remain to be
fully elucidated, structural and functional alternations in
noninfarcted myocardium might be responsible for transi-
tion from a compensatory state to decompensated HF.
The beta-adrenergic receptor (AR) system is a major
regulator of cardiac function. However, long-term stimula-
tion of beta-ARs by overshooting plasma catecholamines
leads to blunting of the beta-AR response in HF. This is
referred to as beta-AR desensitization, which may be
characterized by beta-AR down-regulation and impaired
postreceptor signaling, such as uncoupling the beta-AR
from Gs protein, decreased adenylyl cyclase activity, and
increased Gi protein (2–4). Among these alternations in the
beta-AR system, beta-AR/Gs uncoupling is possibly an
early event of HF (5). The process of uncoupling requires
phosphorylation of agonist-occupied receptor by beta-
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adrenergic receptor kinase-1 (ARK1) (6), which is a mem-
ber of the G-protein–coupled receptor kinase (GRK) fam-
ily, translocating from the cytosol to the cell membrane
when it is activated (6). Interestingly, cardiac beta-ARK1
activity is shown to increase in human HF and experimental
failing myocardium (7,8). Moreover, its activation precedes
the alterations of beta-ARs and G proteins in experimental
HF models (9). A recent experimental study showed that
transgenic mice over-expressing cardiac beta-ARK1 suffered
impaired cardiac function (10). Taken together, myocardial
expression and activation of beta-ARK1 may trigger the
resultant abnormalities of beta-AR signaling cascade,
thereby playing a key role in the development and progres-
sion of HF.
It is well established that the renin-angiotensin system is
associated with cardiac hypertrophy and remodeling. Recent
clinical studies demonstrated that an angiotensin II type 1
receptor blocker (ARB) improves symptoms and exercise
tolerance in patients with HF (11). The angiotensin II type
1 receptor, which couples Gq protein, activates diacylglyc-
erol. Protein kinase C (PKC), a downstream second mes-
senger of the Gq-protein–coupled receptor cascade, is a key
mediator of cell signaling in the pathophysiology of cardiac
hypertrophy and remodeling. Activation of PKC involves
translocation of inactive PKC from the cytosol to the cell
membrane, where diacylglycerol activates it. A previous
experimental study showed that beta-ARK1 activity and
beta-ARK1–dependent receptor homologous desensitiza-
tion are enhanced in cells after PKC activation in vitro (12),
suggesting that PKC activates beta-ARK1 in myocytes in
vivo. Therefore, it is postulated that there is intracellular
“cross-talk” between angiotensin and beta-AR signaling
pathways.
In the present study, we tested the hypothesis that ARB
may improve beta-AR responsiveness in HF by affecting
beta-AR uncoupling through cross-talk between angioten-
sin and beta-AR signaling.
METHODS
Animal models and protocol. All procedures were done in
accordance with the Keio University animal care guidelines,
which conform to the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health. Myocardial infarction was produced in male Wistar
rats weighing 250 to 300 g by ligation of the left coronary
artery. Briefly, rats were anesthetized with intraperitoneal
pentobarbital, 30 mg/kg, and then intubated. The left
coronary artery was ligated 2 to 3 mm from the origin with
a suture (6-0 silk), and the chest was closed immediately
after the distal area paled. The mortality of all animals
operated on in this fashion was approximately 40%. Sham-
operated rats, or shams (n  10), were treated similarly,
except that the coronary suture was not tied. After these
procedures, all rats were freely fed in separate cages. Four
weeks after surgery, the MI rats were randomized to receive
either vehicle (MI/control [C], n  10) or candesartan
cilextil (Takeda Chemical Industries, Ltd., Osaka, Japan) at
10 mg/kg/day for 2 weeks (MI/ARB, n  10). None of the
animals died during the two weeks of treatment with vehicle
or candesartan.
Echocardiographic studies. Echocardiography was per-
formed with the rat under anesthesia, using 30 mg/kg
pentobarbital sodium. Two-dimensional and M-mode im-
ages were obtained using a 7.5-MHz transducer connected
to an ultrasonic echocardiographic system (SONOS 5500,
Phillips Medical Systems, Andover, Massachusetts). Images
for measurements were obtained from parasternal short-axis
views at the mid-papillary muscle level. Measurements were
made using criteria from the American Society of Echocar-
diography (13). The end-diastolic dimension was obtained
at the onset of the QRS complex. The end-systolic dimen-
sion was taken at the instant on maximal lateral position of
the interventricular septum or at the end of the T-wave.
Fractional shortening was calculated: ([end-diastolic dimen-
sion  end-systolic dimension]/end-diastolic dimension)  100.
In addition, the ejection time was measured, and circum-
ferential fiber shortening velocity (Vcf) was calculated:
(fractional shortening/ejection time/100 [circ/s]) (14). All pa-
rameters were measured on five beats and averaged.
Hemodynamic measurements. Hemodynamic data were
obtained before each rat was killed. Mean aortic, LV systolic
and end-diastolic pressures, and maximum and minimum
peak rate of rise in left ventricular pressure (dP/dt) were
obtained. In the subsets of animals from each group,
intravenous isoproterenol (ISO) was administered to assess
LV contractile function under beta-agonist stimulation.
The response of Vcf under stimulation of ISO was also
assessed using echocardiography in the subsets of the
animals.
Terminal thoracotomy. The hearts were excised and
rinsed, and the coronary arteries were perfused with sterile
saline (4°C). The atria, great vessels, and valves were
trimmed away. Transmural samples were separately taken
Abbreviations and Acronyms
ARB  angiotensin II type 1 receptor blocker
AR  adrenergic receptor
ARK1 adrenergic receptor kinase-1
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GRK  G-protein–coupled receptor kinase
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from the infarcted and noninfarcted areas of the LV free
wall. Myocardial samples were then frozen (80°C). Infarct
size was measured by LV dissection and determination of
the percentage of the LV free wall surface area. If the infarct
area was30%, the samples were excluded from the present
study.
Membrane assessment and preparation. Frozen transmu-
ral samples (80°C) were powdered in a stainless-steel
mortar and pestle (also 80°C), placed in tris(hydroxy-
methyl)aminomethane (Tris) buffer, and glass-glass ho-
mogenized, and the contractile proteins were extracted
(0.5 mol/l potassium chloride, 20 min, 4°C). The pellet of a
45,000-g centrifugation was re-suspended in the buffer. The
protein concentration was determined by the method of
Bradford (15).
Beta-AR binding studies. As previously described (16),
beta-ARs were identified using the radioligand (125I)-
iodocyanopindolol (ICYP) (Amersham Biosciences, Pisca-
taway, New Jersey) in eight concentrations (5 to 700 pmol/l)
in saturation isothermal experiments conducted on crude
membrane preparations. Nonspecific binding was defined as
binding in the presence of 104 mol/l ISO. Data are
represented as ICYP specifically bound in femtomoles per
milligram membrane protein (fmol/mg). Competition
binding experiments were performed in duplicate by in-
cubating 50 pmol/l ICYP with ISO using 16 different
concentrations ranging from 1010 mol/l to 103 mol/l.
Nonspecific binding was determined using 1 mol/l pro-
pranolol. The ratio of high- to low-affinity binding sites was
determined using nonlinear regression analysis with the
Prism software program (GraphPad Software Inc., San
Diego, California).
Adenylyl cyclase assays. Methods for measuring adenylyl
cyclase were modified from Salomon et al. (17). The
following agents were used to stimulate adenosine 3,5-
cyclic adenosine monophosphate (cAMP) production in
final concentrations: 10 mol/l ISO, 100 mol/l 5-
guanylylimidodiphosphate (Gpp[NH]p), and 100 mol/l
forskolin.
PKC activity assay. Activity of PKC was measured in
supernatant and particulate fractions from 45,000-g centrif-
ugation of crude myocardial homogenate derived from
noninfarcted myocardium using a PKC enzyme assay kit
(Amersham Biosciences). Tissues were homogenized
in a buffer containing 50 mmol/l Tris/hydrogen chloride at
pH 7.5, 0.3% (wt./vol.) beta-mercaptoethanol, 5 mmol/l
ethylenediamine-tetraacetic acid, 10 mmol/l ethyleneglycol-
tetraacetic acid, 50 g/ml phenylmethylsulfonyl fluoride,
and 10 mmol/l benzamidine. The activity of PKC was
determined by measuring 32P, transferred from (gamma-
32P)-adenosine triphosphate to histone H1, with or without
phosphatidylserine and dioleyl-Sn-glycerol.
Quantification of GRK-2 (beta-ARK-1), GRK-5, and
PKC isoform protein content by immunoblotting.
Assessment of GRK2 and GRK5 was conducted using
standard sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis and immunoblotting techniques, as previously
described (16). Equal amounts of the denatured protein
from each supernatant and particulate fractions from non-
infarcted myocardium were electrophoresed on 10% dena-
turing gel. Proteins were electroblotted onto nitrocellulose
membranes (Amersham Biosciences). Transfer efficiency
was determined by Ponceau staining. Membranes were
incubated in Tris buffered saline containing 3% nonfat dry
milk for 1 h to reduce nonspecific binding of antibody and
developed by conventional methods using each rabbit poly-
clonal antibody (Santa Cruz Biotechnology Inc., Santa
Cruz, California), followed by exposure to horseradish
peroxidase-linked anti-rabbit immunoglobulin (1:5,000 in
blocking buffer). The blots were developed by the enhanced
chemiluminescence method, and bands were visualized after
exposing blots to X-ray film. The densities of each blot were
quantified by densitometric scanning.
Statistics. Data are expressed as the mean value  SEM.
Intergroup comparisons were performed using one-way
analysis of variance and repeated measures analysis of
variance, as appropriate. When a statistical difference was
detected by analysis of variance, the Bonferroni multiple
comparisons procedure was used to define differences be-
tween the results. Statistical significance was defined as p 
0.05. All statistical analyses were performed using Statview
version 5.0 software (SAS Institute Inc., Cary, North
Carolina).
RESULTS
Animal characteristics. As shown in Table 1, the ratio of
LV to body weight was greater in MI/C rats than in shams,
but it was not significantly different between shams and
MI/ARB rats. The infarct weight was similar in MI/C and
MI/ARB rats. Hemodynamic measurement showed that
mean blood pressure was lower and LV end-diastolic
pressure was higher in MI rats than in shams. Echocardio-
graphic findings indicated that the LV dimension increased
and percent fractional shortening decreased in MI rats more
Table 1. Body Weight, LV Weight, Hemodynamics, LV Size,
and LV Function
Sham Operation
Group
(n  8)
MI/C
Group
(n  8)
MI/ARB
Group
(n  8)
BW (g) 418  7 388  19 413  17
LVW/BW (mg/g) 2.1  0.1 2.7  0.1* 2.3  0.1†
Infarct weight (g) — 0.30  0.03 0.30  0.02
HR (beats/min) 405  15 363  14 389  10
mBP (mm Hg) 105  3 88  3* 88  2*
LVEDP (mm Hg) 4  1 17  1* 14  1*
LVEDD (mm) 5.8  0.4 9.7  0.5* 8.9  0.4*
FS (%) 47  3 15  1* 18  1*
*p  0.05 vs sham. †p  0.05 vs MI/C. Data are presented as the mean value  SE.
BW  body weight; FS  fractional shortening; HR  heart rate; LV  left
ventricular; LVEDD  left ventricular end-diastolic dimension; LVEDP  left
ventricular end-diastolic pressure; LVW  left ventricular weight; mBP  mean
blood pressure; MI/ARB  rats with myocardial infarction (MI) treated with the
angiotensin II type 1 receptor blocker candesartan; MI/C  MI rats randomized to
vehicle (control).
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than in shams, although there was no difference in these
indexes between the MI/C and MI/ARB groups.
Beta-AR responsiveness to ISO stimulation. In the basal
condition, maximum dP/dt was lower in MI rats than in
shams, although it was no different between MI/C and
MI/ARB. An increase in maximum dP/dt under ISO
stimulation was attenuated in MI/C but improved in
MI/ARB (Fig. 1). Furthermore, basal and ISO-stimulated
(100 pg/g intravenously) Vcf was measured (n  4 in each
group). Basal Vcf was lower in the MI groups than in sham
group (sham: 6.0  0.1 circ/s; MI/C: 1.7  0.3 circ/s;
MI/ARB: 2.1  0.1 circ/s); however, under ISO stimula-
tion, Vcf was significantly increased in shams and MI/ARB
rats but not in MI/C rats (sham: 8.7  0.3 circ/s; MI/C:
1.8  0.2 circ/s; MI/ARB: 2.6  0.1 circ/s). The percent-
age of increase in Vcf by ISO stimulation was greater in
MI/ARB than in MI/C rats (24  1% vs. 5  1%, p 
0.01).
Radioligand binding studies. The beta-AR number was
not affected by HF after MI (Fig. 2A). The characteristic
reduction in high-affinity binding, denoting uncoupling of
beta-ARs, was noted in myocardial samples from nonin-
farcted regions of MI/C rats. Treatment of MI animals with
ARB increased the proportion of receptors exhibiting high-
affinity agonist binding by 1.7-fold (p  0.01) (Fig. 2B).
Thus, ARB treatment resulted in augmentation in beta-
AR/Gs coupling. The dissociation constant for the high-
affinity site (KH) was similar among the three groups
(sham: 12  6 nmol/l; MI/C: 5  2 nmol/l; MI/ARB: 8 
2 nmol/l). The dissociation constant for the low affinity site
(KL) was also not changed (sham: 3,550  970 nmol/l;
MI/C: 772  289 nmol/l; MI/ARB: 1,966  1,426
nmol/l).
Adenylyl cyclase activity. Basal cAMP production of non-
infarcted myocardium was not affected by HF after MI.
Isoproterenol-stimulated cAMP production was reduced in
MI/C rats but restored by ARB treatment (50% increase vs.
MI/C, p  0.05). On the other hand, cAMP production
under stimulation by 5-guanylylimidodiphosphate and for-
skolin was not significantly different among the three groups
(Fig. 3).
Activity of PKC. Myocardial PKC activity in the particu-
late fraction from noninfarcted viable myocardium of MI/C
animals showed a 46% increase compared with shams (p 
0.05). Treatment with ARB of rats with MI (MI/ARB) was
associated with a 29% reduction in PKC activity in the
particulate fraction, compared with MI/C rats (p  0.05)
(Fig. 4). Activity of PKC in the supernatant fraction did not
significantly differ among the three groups (sham: 32.2 
5.1 nmol/mg/min; MI/C: 32.5  5.8 nmol/mg/min;
MI/ARB: 30.8  2.2 nmol/mg/min; n  5 in each group).
Beta-ARK1 and GRK5 protein content. Immunoblotting
showed that the beta-ARK1 content in the particulate
fraction was increased by 1.5-fold in noninfarcted viable
myocardium of MI/C animals compared with shams (p 
0.001) (Fig. 5A), even though there was no significant
difference in beta-ARK1 content in the supernatant fraction
between the two groups (Fig. 5B). Animals in the MI/ARB
Figure 1. Beta-adrenergic receptor responsiveness to isoproterenol (ISO)
stimulation. In the basal condition, maximum rate of rise in left ventricular
(LV) pressure (dP/dt) was lower in animals with myocardial infarction
(MI) than in shams. An increase in dP/dt under ISO stimulation was
attenuated in untreated MI animals (MI/control [C]) but improved in
candesartan-treated animals (MI/angiotensin II type 1 receptor blocker
[ARB]). *p  0.05 MI/ARB vs. MI/C by repeated measures analysis of
variance; n  4 in each group.
Figure 2. Beta-adrenergic receptor (AR) number (Bmax) and beta-AR/Gs
coupling. (A) The beta-AR number was assessed by a radioligand binding
study. The beta-AR number was not significantly different among the
three groups. (B) A characteristic reduction in high-affinity binding,
denoting uncoupling of beta-ARs, was noted in myocardial samples from
noninfarcted regions of untreated myocardial infarction (MI) animals
(MI/control [C]) compared with shams. Treatment of MI animals with
candesartan (MI/angiotensin II type 1 receptor blocker [ARB]) increased
the proportion of receptors exhibiting high-affinity agonist binding. *p 
0.001 MI/C vs. sham; †p 0.01 MI/ARB vs. MI/C; n 6 in each group.
128 Takahashi et al. JACC Vol. 43, No. 1, 2004
ARB Improves Beta-AR Signaling in LV Remodeling January 7, 2004:125–32
group exhibited a significant reduction in beta-ARK1 pro-
tein level of noninfarcted viable myocardium, compared
with animals in the MI/C group (23% decrease vs. MI/C,
p  0.01) (Fig. 5A), indicating that ARB treatment four
weeks after surgery reversed the beta-ARK1 protein level of
noninfarcted viable myocardium. In contrast, there was no
significant difference in the GRK5 protein content of the
particulate fraction among the three groups (sham: 99  3
arbitrary densitometric units; MI/C: 98  5 arbitrary
densitometric units; MI/ARB: 100  4 arbitrary densito-
metric units; n  6 in each group) (Fig. 5C).
Protein content of PKC-epsilon and other isoforms.
Immunoblotting showed that the PKC-epsilon content in
the particulate fraction was increased in noninfarcted viable
myocardium of MI/C animals by 1.8-fold, compared with
shams (p  0.001) (Fig. 6A), even though there was
no significant difference in PKC-epsilon content in the
supernatant fraction among the groups (Fig. 6B). In con-
trast, the protein content of other PKC isoforms in either
particulate (alpha: 139  5 vs. 138  3 arbitrary densito-
metric units; beta-2: 109  3 vs. 108  3 arbitrary
densitometric units; delta: 150  4 vs. 152  5 arbitrary
densitometric units; zeta: 176  3 vs. 167  3 arbitrary
densitometric units) or supernatant fraction (alpha: 129 3
Figure 3. Adenylyl cyclase activity. Basal 3,5-cyclic adenosine mono-
phosphate (cAMP) production of noninfarcted myocardium was not
affected by heart failure after myocardial infarction (MI). Isoproterenol
(ISO)-stimulated cAMP production was reduced in untreated MI animals
(MI/control [C]) but increased in candesartan-treated animals (MI/
angiotensin II type 1 receptor blocker [ARB]). On the other hand,
cAMP production under stimulation by 5-guanylylimidodiphosphate
(Gpp[NH]p) and forskolin was not significantly different among the three
groups. *p  0.05 MI/C vs. sham; †p  0.05 MI/ARB vs. MI/C; n  6
in each group.
Figure 4. Activity of protein kinase C (PKC). Myocardial PKC activity in
the particulate fraction was increased in noninfarcted viable myocardium of
the untreated myocardial infarction (MI) animals (MI/control [C]) com-
pared with shams. Treatment of MI animals with candesartan (MI/
angiotensin II type 1 receptor blocker [ARB]) reduced PKC activity in the
particulate fraction, compared with MI/C. *p 0.05 MI/C vs. sham; †p
0.05 MI/ARB vs. MI/C; n  5 in each group.
Figure 5. Beta-adrenergic receptor kinase 1 (ARK1) and G-protein–
coupled receptor kinase (GRK) 5 protein content. (A) Immunoblotting
showed that the beta-ARK1 content in the particulate fraction was
increased in noninfarcted viable myocardium of the untreated myocardial
infarction (MI) animals (MI/control [C]) as compared with shams. Rats
with MI treated with candesartan (MI/angiotensin II type 1 receptor
blocker [ARB]) exhibited a reduction in beta-ARK1 protein level of
noninfarcted viable myocardium, as compared with MI/C rats. (B) Immu-
noblotting showed that there was no significant difference in beta-ARK1
content in the supernatant fraction among the groups. (C) Representative
immunoblots for GRK5 are shown. The GRK5 protein content in the
particulate fraction did not change among the three groups. *p  0.001
MI/C vs. sham; †p  0.01 MI/ARB vs. MI/C; n  6 in each group.
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vs. 129  3 arbitrary densitometric units; beta-2: 133  3
vs. 138  3 arbitrary densitometric units; delta: 111  3 vs.
112  4 arbitrary densitometric units; zeta: 138  4 vs. 140
 3 arbitrary densitometric units) did not change in the
MI/C animals compared with shams (n  6 in each group).
These data indicate that PKC-epsilon was selectively acti-
vated with translocation from the cytosol to the membrane
in post-MI remodeled myocardium. In addition, ARB
treatment of MI animals resulted in a significant reduction
in the myocardial PKC-epsilon protein level in the partic-
ulate fraction, compared with untreated MI animals (26%
reduction, MI/ARB vs. MI/C, p  0.001) (Fig. 6A).
DISCUSSION
The current study demonstrated that beta-AR desensitiza-
tion in postinfarction LV remodeling was associated with
reductions in the percentage of high-affinity sites of
beta-AR and in ISO-stimulated cAMP production and
with increased protein levels of beta-ARK1 in noninfarcted
viable myocardium. The epsilon isoform of PKC, but not
other PKC isoforms, was up-regulated at the protein level in
noninfarcted myocardium of untreated post-MI animals
with increased total PKC activity. Treatment with an ARB
for two weeks did not reverse LV size and fractional
shortening in the basal condition, but beta-AR–mediated
inotropic responsiveness was improved by ARB treatment,
accompanied by an increase in the proportion of myocardial
beta-ARs that are coupled to Gs. In addition, we observed
that up-regulation of beta-ARK1 and PKC-epsilon levels
and activation of PKC in noninfarcted myocardium were
inhibited by ARB treatment. These data suggest that
treatment with an ARB improves beta-AR desensitization
associated with HF after MI, specifically by affecting beta-
AR/Gs coupling in noninfarcted myocardium during the
development of LV remodeling.
Beta-AR desensitization in HF after MI. Adrenergic
activation in HF is associated with altered beta-AR signal-
ing, including beta-AR down-regulation, uncoupling of
beta-AR from the Gs protein, and decreased adenylyl
cyclase activity (3,4,18). The desensitization of beta-AR
caused by these factors facilitates a further activation of the
sympathetic nervous system, resulting in myocyte damage
due to some toxic effects of catecholamines, such as calcium
overloading. Furthermore, activation of the sympathetic
nervous system is related to the susceptibility to fatal
arrhythmia, sudden death, and induction of ischemia (19).
Thus, long-term adrenergic activation and desensitization
of the beta-AR system may play a role as a trigger for the
vicious cycle seen in decompensated HF. We confirmed the
occurrence of beta-AR desensitization in the present study,
using an animal model of post-MI HF that mimics many of
the features of clinical HF.
The precise molecular mechanisms for depressed
beta-AR responsiveness in HF have not been fully clarified.
Since the original description of beta-AR desensitization in
the human myocardium (18), various abnormalities of its
signal transduction pathway have been shown in different
models of HF. Maurice et al. (20) reported functional
uncoupling of myocardial beta-ARs in a rabbit post-MI
model with increased beta-ARK1 levels and activity, com-
pared with sham-operated animals. In the present study,
there was a significant reduction in the proportion of
beta-ARs coupled to the Gs protein, and immunoblotting
showed that the membrane level of beta-ARK1, but not
GRK5, was up-regulated in noninfarcted myocardium of
untreated post-MI rats compared with shams, which is
consistent with their findings. Although the precise mech-
anisms for beta-AR desensitization associated with HF are
Figure 6. Protein content of protein kinase C (PKC)-epsilon. (A) Immu-
noblotting showed that the PKC-epsilon content in the particulate fraction
was increased in noninfarcted viable myocardium of the untreated myo-
cardial infarction (MI) animals (MI/control [C]) as compared with shams.
Candesartan treatment of MI animals (MI/angiotensin II type 1 receptor
blocker [ARB]) reduced the PKC-epsilon protein level in the particulate
fraction, as compared with MI/C. (B) Immunoblotting showed that there
was no significant difference in PKC-epsilon content in the supernatant
fraction among the three groups. *p  0.001 MI/C vs. sham; †p  0.001
MI/ARB vs. MI/C; n  6 in each group.
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still unclear, our results suggest that beta-AR/Gs uncou-
pling induced by up-regulation of the beta-ARK1 level is
responsible for beta-AR desensitization in noninfarcted
myocardium, rather than down-regulation of the global
myocardial beta-ARs.
Role of PKC in cardiac hypertrophy and failure.
Activation of PKC is important for multiple cardiovascular
functions and pathophysiologic conditions, including myo-
cardial protection against ischemic injury, cardiac hypertro-
phy, interstitial fibrosis, and HF (21). The distribution of
the various PKC isoforms is tissue- and species-dependent.
In adult rat cardiomyocytes and myocardium, PKC isoforms
epsilon and delta seem to be maintained with age, whereas
other PKC isoforms may decline (22,23). In human myo-
cardium, PKC isoforms alpha, beta-1/2, delta, and epsilon
have also been reported (24). In the present study, PKC-
epsilon, but not other PKC isoforms, was up-regulated in
noninfarcted myocardium of the untreated post-MI rats. To
date, PKC-epsilon, which is a major hormonally responsive
PKC isoform in mammalian cardiac myocytes, is believed to
be involved in cardiomyocyte growth and ischemic precon-
ditioning (25,26). Acute mechanical stretch of the LV
induces translocation of PKC-epsilon (27) and chronic
pressure overload by aortic banding activated PKC-alpha
and -epsilon in the guinea pig heart (28). Activation of
PKC-epsilon has also been found to contribute to Gq
overexpression-induced cardiac hypertrophy and failure
(29). Based on these findings, it is possible that PKC-
epsilon plays an important role in cardiac hypertrophy and
failure in noninfarcted myocardium during postinfarction
LV remodeling.
Effect of ARB on beta-AR signaling in HF. Recently,
Makino et al. (30) reported that angiotensin-converting
enzyme inhibitor or ARB had an effect of preserving
myocardial beta-AR signaling in an MI model using rab-
bits. In their study, ARB treatment was started immediately
after coronary ligation and continued for three weeks,
resulting in limited cardiac remodeling and improved sys-
tolic dysfunction. Therefore, the effect of ARB on beta-AR
signaling might be secondary to hemodynamic improve-
ment and limited LV remodeling. In contrast, we started
administration of ARB to post-MI rats four weeks after
surgery, when LV remodeling had definitely developed.
Treatment with ARB for two weeks did not influence basal
LV function and hemodynamics but improved myocardial
beta-AR responsiveness. These findings may suggest a
primary effect of ARB on myocardial beta-AR signaling.
Ramos-Ruiz et al. (31) have demonstrated that the activity
of the beta-ARK1 promoter is stimulated by activation of
the Gq/PKC signaling pathway in aortic smooth muscle
cells. Although the mechanism for the increased beta-
ARK1 level in HF is not certain, existing evidence suggests
that PKC can directly regulate beta-ARK activity to en-
hance beta-AR phosphorylation and initiate desensitization
(12). In the present study, the inhibitory effect of treatment
with candesartan on cardiac beta-ARK1 expression could be
potentially explained by altering cardiac PKC activity and
expression. We also found that PKC-epsilon was selectively
increased in noninfarcted viable myocardium from post-MI
rats; treatment of HF animals with candesartan was associ-
ated with a reduced cardiac PKC-epsilon content. These
data suggest a possible mechanism by which an ARB
influences the cardiac beta-ARK1 content: treatment with
candesartan, by reducing angiotensin II-mediated PKC
activation, may reduce beta-ARK1 translocation.
Study limitations and implications. The long-term
effect of ARB on the development of LV remodeling after
MI was not determined in the present study. However, we
have found that short-term ARB treatment during the
chronic phase of MI is associated with a reduced myocardial
beta-ARK1 level, resulting in enhanced beta-AR respon-
siveness. These data suggest a plausible explanation for the
observation that an ARB has a favorable effect on exercise
tolerance and symptoms in patients with HF (32). Al-
though beta-ARK1 and PKC-epsilon may play important
roles in the mechanisms of this phenomenon, multiple
pathways could have been independently influenced by
ARB treatment. Further experiments using PKC-epsilon
knockout mice or selective inhibitor of PKC-epsilon would
be needed to confirm the intracellular cross-talk between
beta-AR and angiotensin signaling through beta-ARK1 and
PKC-epsilon.
Conclusions. Treatment with ARB during the chronic
phase of MI improved beta-AR coupling in noninfarcted
myocardium, even though there was no change in basal LV
function. Cross-talk between beta-AR and angiotensin
signaling through beta-ARK1 and PKC-epsilon may be
responsible for the phenomenon.
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